Interactions happen when one drug influences the level or activity of another. Because of the way they are processed in the body, protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) are especially likely to be involved. Interactions may raise blood levels of a drug, possibly causing intensified side effects, or they may decrease drug concentrations, potentially resulting in reduced effectiveness. But drug interactions are not always problematic: the PI ritonavir (Norvir) can "boost" levels of other drugs in its class, increasing their potency and allowing for more convenient dosing.
With so many drugs to consider, it is not possible to give a comprehensive listing of every possible interaction. Instead, this article will discuss how and why drug interactions occur, describe some of the important interactions commonly seen with antiretroviral therapy, and offer steps to avoid or manage them. The accompanying resource list provides useful online drug interaction databases and tools to help determine whether specific medications are likely to interact.
These are just a few of the interactions between anti-HIV medications and other drugs that have been announced in "Dear Doctor" advisories or described in medical journals during the past year. As novel agents are approved and additional information about existing products becomes available, new interactions continually come to light. Uncovering potential interactions is a major focus of the drug development process and -- as shown by the amount of time and space devoted to the topic at professional conferences and in the medical literature -- avoiding and managing drug interactions has become an increasingly important part of HIV medicine.
Today most HIV positive people receiving treatment take antiretroviral regimens consisting of three or more drugs from at least two different classes. Many also use various medications, such as antifungals and cholesterol-lowering statins, to treat associated conditions and manage side effects. OTC medications, street drugs, methadone, alternative and complementary therapies, and even certain foods may also be involved in interactions.
This exploding "polypharmacy" presents a challenge for people with HIV and their providers. While many drug interactions are of little clinical significance, others can lead to severe toxicities, loss of virological control of HIV, and the emergence of drug-resistant virus. Fortunately, a relatively small subset of drugs is implicated in the lion's share of interactions; often problems can be avoided by heightened vigilance and judicious substitution of effective alternatives.
Pharmacodynamic interactions are those related to the combined clinical activity of two or more agents used together, for example, additive or synergistic side effects (see below). Pharmacokinetic interactions occur when one agent changes the blood concentration of another. The majority of clinically significant drug interactions encountered in HIV medicine are pharmacokinetic in nature.
PHARMACODYNAMICS: What the drug does to the body
PHARMACOKINETICS: What the body does to the drug
Successful HAART relies on additive effects. Not long after the advent of the first antiretroviral drugs, it became clear that single agents used alone (monotherapy) could not suppress HIV over the long term since the virus can mutate to develop drug resistance. Therefore, multiple agents from more than one drug class are now used to construct effective regimens.
Additive and synergistic side effects are a major concern in anti-HIV therapy. When two or more drugs with overlapping toxicity profiles are used together, the combined toxicity may prove intolerable, even if the individual agents alone produce only mild side effects. For instance, the "d drugs" -- ddC (zalcitabine, Hivid), ddI (didanosine, Videx), and d4T (stavudine, Zerit) -- can all cause pancreatitis (inflammation of the pancreas), peripheral neuropathy (nerve damage), and mitochondrial toxicity. Thus, experts recommend that combinations of these drugs should be avoided if possible.
In a nutshell, the plasma concentration of a drug varies between doses. The goal is to achieve a minimum, or trough, concentration (Cmin) that is effective without causing unacceptable toxicity at the highest, or peak, level (Cmax). The total exposure to a drug between one dose and the next is called the area under the curve, or AUC. If a drug has a narrow therapeutic range -- meaning a small difference between an effective dose and toxic one -- even minor interactions may prove problematic.
Medications that neutralize the acidity of gastric secretions (that is, increase their pH) can interfere with the absorption of other drugs, such as atazanavir, that require an acid environment. The old formulation of ddI contained an antacid buffering agent and thus could not be taken at the same time as several other drugs; this is not a concern with the newer, long-acting enteric-coated form of ddI (Videx EC). For the same reason, certain drugs should not be taken with acid-lowering medications. In addition, some agents can combine with one another in the stomach (a process called chelation), resulting in insoluble compounds that cannot be absorbed; this can occur when some drugs are taken with certain minerals.
The initial phase of drug absorption and metabolism occurs in the intestines. Cells in the intestinal lining contain transporter proteins, called P-glycoproteins, that act as "pumps" to return drug molecules back into the intestine for excretion rather than allowing them to enter the bloodstream. P-glycoproteins also pump certain drugs out of individual cells throughout the body and are associated with drug resistance. Agents that promote P-glycoprotein activity (including some antiretroviral drugs) cause lower plasma drug concentrations, while P-glycoprotein inhibitors increase drug levels.
Once successfully absorbed, the drug enters the bloodstream. Agents are carried in the plasma in either a free (unbound) form or bound to blood proteins such as albumin; the bound form is not bioavailable and cannot enter tissues. Thus, agents that alter protein binding can affect how much active drug reaches a site of action.
There are some two dozen CYP450 isoenzymes (specific variants), classified into families designated by numbers and letters, but a small subset carries out most drug metabolism. Many agents are metabolized by a single isoenzyme, but others are processed by more than one. The most abundant isoenzyme, CYP3A4, is responsible for metabolizing about half of the drugs currently on the market.
Drug metabolism is limited by the quantity of CYP450 enzymes, and different agents compete for their use. Some drugs, called CYP450 inhibitors, retard the activity of these enzymes (ritonavir and erythromycin are examples of inhibitors). When an inhibitor of a specific isoenzyme is present, the processing of other drugs that require the same enzyme is slowed, causing blood concentrations of these other drugs to increase. (This is why ritonavir can be used to boost levels of other PIs; see "The Benefits of Boosting" below.) Other agents, called CYP450 inducers, cause cells to produce more of a specific isoenzyme over time (rifampin and phenytoin are examples of inducers). When such an agent is present, drugs that are metabolized by the now more abundant isoenzyme are processed more rapidly, causing their blood concentration to fall.
After they are processed and distributed to tissues, drugs must be eliminated. Some drug metabolites are excreted in bile and eliminated through the feces, while others are processed by the kidneys and eliminated in the urine. Any factors that impair or inhibit the filtering activity (tubular secretion) of the kidneys can slow the processing of drugs that rely on this mechanism, again allowing them to reach higher plasma concentrations. For this reason, people with renal insufficiency (kidney dysfunction) are more prone to drug interactions and side effects.
As described by Stephen Piscitelli, PharmD, and Keith Gallicano, PhD, in an overview of antiretroviral and OI drug interactions in the March 29, 2001 issue of the New England Journal of Medicine (NEJM), pharmacokinetic interactions among drugs used in HIV therapy are often "multifactorial," involving altered drug absorption, P-glycoprotein modulation, CYP450 induction and/or inhibition, changes in renal elimination, and fluctuations in intracellular drug concentration.
The impact of liver disease is of particular concern since a substantial proportion of HIV positive people have chronic hepatitis B or C coinfection, which can lead to liver damage including fibrosis and cirrhosis (scarring). When the liver is damaged -- as a result of viral hepatitis, heavy alcohol use, drug toxicity, or some other cause -- its ability to process drugs may be impaired, potentially leading to higher blood concentrations.
As reviewed by David Wyles, MD, and John Gerber, MD, in the January 1, 2005 issue of Clinical Infectious Diseases (CID), several studies have shown that the pharmacokinetics of antiretroviral drugs may be significantly altered in HIV positive people with hepatitis B or C, and that such impairment is more pronounced in those with more advanced liver damage. For example, L. Becquemont and colleagues demonstrated that CYP3A4 and CYP2D6 isoenzyme activity decreased by 65% and 81%, respectively, in HCV-infected subjects compared with uninfected individuals. At the functional level, other research has demonstrated impaired drug clearance in people with liver damage.
Wyles and Gerber concluded that liver dysfunction has a considerable impact on PI metabolism, but on the whole, NNRTI and nucleoside reverse transcriptase inhibitor (NRTI) processing are minimally affected. Fortunately, altered drug metabolism in people with liver damage can often be managed by adjusting drug doses. The authors cautioned, however, that making generalized recommendations for dose reduction is difficult, "given the highly variable pharmacokinetics of PIs across the population."
Tenofovir DF (Viread), the only approved nucleotide reverse transcriptase inhibitor, has some unique interactions. Tenofovir can increase plasma levels of both buffered and enteric-coated ddI dramatically (by more than 50% in some studies). In one case, a man with pre-existing kidney dysfunction died of kidney failure and lactic acidosis (a known side effect of ddI) after taking the two drugs together. When using this combination, the ddI dose should be reduced and individuals should be monitored for ddI-related toxicities. Tenofovir can decrease blood concentrations of atazanavir, so levels of this PI should be increased through higher dosing or boosting with ritonavir. Conversely, atazanavir -- as well as lopinavir -- increases tenofovir levels, but dose adjustment is generally not necessary; tenofovir does not appear to interact with saquinavir, nelfinavir, or indinavir (Crixivan).
Nevirapine and efavirenz speed processing and reduce plasma concentrations of other drugs metabolized by CYP3A4. In particular, these NNRTIs can cause levels of some PIs to fall, necessitating higher doses and/or boosting with ritonavir. They also lower concentrations of a variety of other agents metabolized by the CYP450 system, including methadone and oral contraceptives, potentially resulting in decreased efficacy.
Efavirenz and delavirdine (which is no longer recommended for first-line therapy) can increase levels of some PIs and other types of medication metabolized by the liver. Caution is advised when combining these NNRTIs with drug classes that can reach potentially dangerous concentrations when used with CYP450 inhibitors.
Given its mixed inducer/inhibitor effect, as well as its purported influence on other isoenzymes besides CYP3A4, efavirenz can increase nelfinavir and ritonavir levels even though it decreases concentrations of atazanavir, lopinavir, indinavir, saquinavir, and fosamprenavir (Lexiva). Efavirenz has been shown to lower atazanavir concentrations by about 75%; while its effect on other PIs is less dramatic, it should not be used with unboosted indinavir or saquinavir.
Caution is warranted when combining NNRTIs with CYP450 inducers such as rifampin, since these can lower NNRTI levels. It is also important to remember that NNRTIs have long half-lives, meaning they stay in the body for an extended period after discontinuation; this should be taken into account when stopping an NNRTI and substituting a potentially interacting drug. A final caveat with nevirapine is to avoid or use with caution other drugs that may cause skin rash or liver toxicity, due to the potential for overlapping side effects.
Saquinavir has the mildest CYP3A4 inhibitory effect, and is therefore the least likely to affect levels of other drugs. Atazanavir, fosamprenavir, indinavir, and nelfinavir are all moderate inhibitors. In contrast, ritonavir is so potent in this respect that it can be used to boost blood concentrations of other drugs in its class (see "The Benefits of Boosting" below). Unlike other approved PIs, ritonavir and nelfinavir both also induce CYP3A4, and share the interesting property of being able to induce their own metabolism. Little is known about the use of lopinavir alone, since it is coformulated with ritonavir in the Kaletra combination pill.
Interactions between antiretroviral medications are not always a bad thing. In the case of ritonavir, the drug's unique interaction profile allows it to be used to "boost," or increase, blood concentrations of other PIs. Ritonavir works well as a pharmacological enhancer because it inhibits both the initial stages of PI metabolism in the intestines and CYP3A4 processing in the liver.
This capacity has given ritonavir a new lease on life as a low-dose (typically 100 mg) adjunct drug. At the same time, use of full-dose ritonavir has fallen out of favor because its propensity to raise levels of so many medications is more often harmful than beneficial. Low-dose ritonavir has also boosted the fortunes of other first-generation PIs (namely indinavir and saquinavir) by dramatically reducing their high pill burdens, loosening food requirements, and allowing them to be taken fewer times per day.
Today's experimental PI candidates are routinely tested in conjunction with ritonavir. Abbott hit the jackpot with Kaletra, a combination pill containing lopinavir (a second-generation PI) plus a small dose of ritonavir. But the company raised the ire of the HIV community when it increased the price of low-dose ritonavir by 400% in December 2003 -- an attempt, some charged, to give Kaletra a price edge over other PIs.
Researchers are avidly searching for other drugs that can also be used as pharmacological boosters. A few of the approved PIs -- including nelfinavir, which has an interaction profile somewhat similar to that of ritonavir -- have been linked to increased concentrations of other PIs in some studies. But to date none has demonstrated a strong enough or consistent enough effect to give ritonavir a run for its money.
Like all CYP450 inhibitors, PIs slow the processing of other medications metabolized by the same isoenzymes, potentially allowing them to reach highly toxic concentrations. Full-dose ritonavir presents the greatest risk; the smaller ritonavir dose in the Kaletra pill (100 mg) or used to boost other PIs is less likely to cause problematic interactions. Some of the drugs that warrant extra caution or should be avoided altogether when used with PIs include certain statins, anticonvulsants, benzodiazepines, and calcium-channel blockers. (Problematic drug classes are discussed in more detail below.)
Because PI interaction profiles vary in some important respects, each new drug in this class must be extensively tested to determine how it will behave under "real world" conditions. For example, as reported in the January 28, 2005 issue of AIDS, a recent clinical trial (ACTG 5143) revealed that combining fosamprenavir plus lopinavir led to significantly reduced levels of both amprenavir (the active metabolite of fosamprenavir) and lopinavir; as a result, enrollment in the study was halted. Unlike most of its classmates, tipranavir (Aptivus), a nonpeptidic PI recently granted approval, is a CYP3A4 inducer. In a study by Sharon Walmsley, MD, and colleagues presented at the XV International AIDS Conference in Bangkok in July 2004, tipranavir reduced minimum plasma concentrations of amprenavir (Agenerase), lopinavir, and saquinavir by 51%, 45%, and 84%, respectively. As such, tipranavir should be avoided or used cautiously in conjunction with other PIs.
Even as PIs impact levels of other drugs metabolized by the CYP450 system, they themselves are subject to alteration by CYP450 inducers and inhibitors. Inducers present the most concern since they can potentially lead to subtherapeutic PI levels, viral breakthrough (increase in viral load), and the development of drug-resistant HIV.
For the most part, the drugs discussed below are CYP450 substrates. To refresh, agents that inhibit CYP450 enzymes tend to increase concentrations of other drugs, while agents that induce CYP450 enzymes usually decrease drug concentrations. In actual practice, most of the following medications are of concern either because they reduce antiretrovirals to subtherapeutic levels, or because anti-HIV drugs raise them to dangerously toxic levels. However, for almost every general rule about interactions between drug classes, there are exceptions and special cases.
HIV positive individuals should educate themselves about common drug interactions and health-care professionals should keep up to date with the medical literature in this field, and especially with advisories issued by the Food and Drug Administration (FDA) or pharmaceutical companies regarding newly discovered interactions. Monitoring for effectiveness and toxicity should be performed regularly, especially when adding or changing medications.
Macrolide antibiotics, including erythromycin and clarithromycin (Biaxin), also inhibit both CYP3A4 and P-glycoprotein. As reported in the September 9, 2004 issue of NEJM (and summarized in the last issue of BETA), erythromycin appears to increase the risk of fatal cardiac arrhythmias (heart rhythm disturbances) when coadministered with drugs metabolized by CYP3A4. Although the authors of this study did not look at PIs specifically, they found that subjects using erythromycin along with other CYP3A4 inhibitors had a risk of sudden cardiac death five times higher than that seen in individuals not taking such a combination. A related macrolide, azithromycin (Zithromax), has a minimal effect on CYP450 enzymes and may be a suitable alternative to erythromycin or clarithromycin.
Interactions between antiretrovirals and drugs used to treat tuberculosis (TB) are a growing concern, especially in resource-limited countries where TB remains a major cause of AIDS-related death. Rifampin (known as rifampicin outside the U.S.), part of standard first-line regimens for TB prophylaxis and treatment, is one of the most potent CYP3A4 inducers known, and can reduce PIs to subtherapeutic levels. The optimal regimen for treating active TB in people with HIV remains unclear; physicians must weigh the superior efficacy of rifampin against concerns about interactions with antiretroviral drugs.
The azoles, macrolides, and rifamycins can interact not only with antiretrovirals, but also with each other. On account of this complexity, the care of HIV positive people who require treatment for multiple OIs should be managed by experienced physicians.
Other types of acid-lowering agents are much longer-acting. Proton pump inhibitors (e.g., omeprazole [Prilosec], esomeprazole [Nexium], lansoprazole [Prevacid]), which block the production of stomach acid, can alter gastric pH for 24 hours or longer. In December 2004 Bristol-Myers Squibb warned against the use of ritonavir-boosted atazanavir plus omeprazole after a study revealed a 76% reduction in atazanavir plasma concentrations when the drugs were coadministered. (The study used the 40 mg prescription dose of omeprazole; it is not known whether the 20 mg OTC dose would have a similar effect.) Data are forthcoming on the safety of atazanavir plus histamine-2 (H2) receptor antagonists, another class of acid-lowering agents that includes cimetidine (Tagamet) and ranitidine (Zantac).
One class of commonly used cholesterol-lowering agents, the "statins," are metabolized by the CYP450 system and their concentrations can be increased by PIs (particularly ritonavir). But not all statins are equal. In November 2000 the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group recommended that people on HAART should start with low doses of pravastatin (Pravachol), atorvastatin (Lipitor), or fluvastatin (Lescol), which appear to interact least with antiretrovirals. The panel advised against use of lovastatin (Mevacor) or simvastatin (Zocor), which can reach dangerously high levels when used with PIs, potentially leading to intensified side effects including rhabdomyolysis (muscle damage) and kidney failure. The interaction profile of the newest statin, rosuvastatin (Crestor), has not yet been well defined.
Among the benzodiazepines, a class of sedatives used to treat anxiety and insomnia, midazolam (Versed) and triazolam (Halcion) may reach dangerously high concentrations when used with CYP450 inhibitors, potentially causing fatal respiratory depression. Caution is also warranted concerning alprazolam (Xanax), diazepam (Valium), and zolpidem (Ambien). Safer alternatives include lorazepam (Ativan) and temazepam (Restoril).
Among medications used to treat depression, drugs in the tricyclic antidepressant class are most likely to be involved in CYP450-mediated interactions. Levels of the more commonly used selective serotonin reuptake inhibitors (SSRIs) -- including fluoxetine (Prozac), paroxetine (Paxil), sertraline (Zoloft), and escitalopram (Lexapro) -- may also be increased by CYP450 inhibitors; excessive SSRI levels can cause symptoms such as seizures, heart rhythm abnormalities, and coma. When taken with PIs, especially ritonavir, antidepressant doses may need to be reduced. Here again, drug level monitoring may help avoid interaction problems.
Many people with HIV see separate providers for HIV-related and mental health care. Due to the potential for antiretroviral and psychiatric drug interactions, it is important that all providers know about all the drugs their patients are using and work together to determine appropriate regimens.
PIs can also interact dangerously with immunosuppressive drugs (e.g., tacrolimus [Prograf]) used to prevent organ rejection after a transplant. One HIV positive liver transplant recipient at the University of Pittsburgh died from an organ rejection reaction several years ago when his hometown doctor took him off HAART, thereby causing his tacrolimus level to drop precipitously. This case illustrates the importance of physicians working together to determine appropriate medication combinations.
Evidence suggests that ritonavir can increase blood concentrations of ecstasy (MDMA, "X"), which is metabolized by the CYP2D6 isoenzyme. Elevated ecstasy levels may cause heightened agitation, seizures, increased heart rate, and/or cardiac arrest. The October 1996 death of a London man with pre-existing liver disease was widely attributed to concurrent use of ritonavir (which he had recently started) and a moderate dose of ecstasy (reportedly 2.5 tablets). Other forms of amphetamine, including crystal methamphetamine ("speed," "crank," "Tina"), share the same processing pathway and may have comparable interaction profiles. However, cocaine, also a stimulant, has not been reported to interact with antiretroviral medications.
Another worrisome party drug is gamma-hydroxybutyrate, or GHB. The combination of ritonavir, saquinavir, and modest doses of GHB and ecstasy may have been responsible for the nearly fatal respiratory arrest of a Seattle man reported in 1999. While there are minimal human data available, animal studies suggest that GHB is metabolized by the CYP450 system.
In both the London and Seattle cases, the individuals were found to have unusually high blood levels of their respective recreational drugs, but this may have been due to other factors (e.g., adulterated drugs, genetic variations in drug-processing enzymes) and cannot be definitively attributed to interactions with anti-HIV drugs.
Finally, ritonavir, other PIs, efavirenz, and nevirapine appear to reduce plasma concentrations of opiates (e.g., heroin, numerous prescription pain-relievers), which could potentially reduce the risk of overdose, but may lead to withdrawal symptoms or inadequate pain relief.
Physicians and methadone maintenance program staff should be aware of this potential effect, which may take as long as two weeks to fully emerge, and be prepared to monitor methadone levels and gradually increase methadone doses enough to avoid opiate withdrawal (perhaps by 25% or so).
Garlic (Allium sativum) inhibits CYP3A4 activity, and high-dose garlic supplements reduced saquinavir levels in one study; however, the smaller amount of garlic normally consumed in food is unlikely to cause problems. Another herbal remedy that could interact pharmacokinetically with anti-HIV medications is milk thistle (and its derivative, silymarin), used to treat liver conditions including chronic hepatitis B and C.
Grapefruit juice -- not an herbal remedy but a botanical product nonetheless -- received considerable attention in the late 1990s as a proposed strategy to boost plasma saquinavir concentrations. While grapefruit juice does affect CYP3A4 activity in the intestines, it does not appear to cause clinically significant interactions with approved PIs or NNRTIs.
Herbal remedies and nutritional supplements are not closely regulated like drugs, and it is not always easy to determine the exact ingredients or amounts of various substances in these products. To reduce the risk of interactions, people with HIV should inform their health-care providers about any alternative or complementary therapies they are using or considering.
The best way to minimize the risk of drug interactions is to remain vigilant. There is no need to memorize every possible interaction -- even HIV/AIDS professionals find it difficult to keep up with the ever-growing list. Instead, become familiar with how drugs are metabolized, the major interaction mechanisms, and which drug classes are most likely to cause problems. With this background, refer to databases and tools like those listed in the sidebar on page 28. When considering a regimen change, do some research and ask about potential interactions. Pharmacists, who specialize in drugs and their pharmacokinetics, can be an excellent resource.
People with HIV should inform their health-care team (general practitioners, specialist physicians, nurses, alternative and complementary therapy providers) about all the medicinal products they are using: prescription drugs, OTC medications, recreational or street drugs, and alternative or complementary therapies including herbs and nutritional supplements. Piscitelli recommends putting all these products in a bag and bringing them along to appointments so providers can see for themselves what their patients are using. He also emphasizes the importance of reviewing an individual's complete regimen at each visit. It is good practice to consider the possibility of a drug interaction if an antiretroviral regimen does not seem to be working as well as it should (e.g., rising viral load, decreasing CD4 cell count) or if a person experiences new, unusual, or severe side effects.
HIV positive people need not despair if they must take a medication implicated in many interactions. Often, drug interactions can be overcome simply by raising or lowering doses; however, this should never be done without the guidance of a knowledgeable practitioner. In other cases, it may be possible to replace an interacting drug with a noninteracting agent that works comparably well. Any time a new or unusual interaction comes to light, it should be reported promptly to the drugs' manufacturers and the FDA so that interaction databases can be updated and other people with HIV can benefit from this increasing body of knowledge.
Antiretroviral Drugs May Interact With*
* not a comprehensive listing
For Further Reading
Package inserts for approved drugs -- included with purchased medications or available from a pharmacist or on the internet. Check pharmaceutical company web sites; most have sites for specific drugs, often with URLs that include the drugs' brand names (e.g., www.reyataz.com)
HIV Drug-Drug Interactions -- The Body's listing of the latest drug interaction news, research, tools, and specific medication alerts
Polypharmacy Problems: Drug Interactions in the Multidrug Therapy of HIV Infection -- article by Alice Pau, PharmD, and Tim Horn. PRN Notebook, March 2002; includes interaction charts featuring lipid-lowering agents, herbal/nutraceutical therapies, and illicit/recreational drugs
What's PK Got to Do With It? -- the Winter 2005 issue of Positively Aware features a series of articles on pharmacokinetic basics and how the three major antiretroviral drug classes work and interact
Clinically Significant Drug Interactions Associated with Highly Active Antiretroviral Therapy -- article by John Faragon, PharmD, and Peter Piliero, MD. HIV Education Prison Project, January 2004; accompanying chart, Drug Interactions with HAART and Methadone
Drug Interactions: HIV Medications, Street Drugs and Methadone -- article by James Learned and Maia Szalavitz. ACRIA Update, Spring 2005
Drug Interaction Resources: Online Tools and Databases
University of Liverpool -- comprehensive and frequently updated online database of antiretroviral drug interactions; includes charts in PDF format and an interactive database access tool
HIV InSite -- interactive tool allows searches by antiretroviral drug, interacting drug, and interacting drug class; the site also includes ARV Alert, featuring the latest safety alerts about antiretroviral drug interactions and adverse events
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents -- Table 19: Drugs That Should Not Be Used With PI or NNRTI Antiretrovirals; Table 20: Drug Interactions Between Antiretrovirals and Other Drugs
AIDSmeds.com -- simple tool for checking antiretroviral drug interactions
Project Inform -- comprehensive list of interactions by drug; also includes a glossary and information about street drug interactions
Party Smarty Marty -- resource on interactions between anti-HIV medications and recreational drugs sponsored by the San Francisco Community Clinic Consortium and the Haight-Ashbury Free Clinic
Drug Digest -- includes drugs for all conditions and herbs by both common and Latin names; includes food and alcohol as well as drug-drug interactions
Medscape HIV/AIDS Clinical Calculator -- checks interactions among drugs in a regimen and suggests appropriate dosing schedules
Liz Highleyman (email@example.com) is a freelance medical writer and editor based in San Francisco.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.